The original version of this story appeared in Quanta Magazine. Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since ...

Block’s Q3 2025 earnings jumped 64% year over year as the company shifted from losses two years ago to consistent quarterly profits. The stock trades at 13x trailing earnings versus the S&P 500’s 21x ...

Dec 8 (Reuters) - Recursion Pharma, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in ...

The financial-technology sector has struggled to live up to its pandemic-era heyday, and that has meant some pain for Block investors recently. Heading into Wednesday, shares of Block XYZ had lost 12% ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

One of the most competitive corners of global finance is becoming even more extreme as bankers take big risks to outmaneuver rivals for lucrative block trades in Australia. These large chunks of stock ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

Shares of Block tumbled 11% in after hours trading on Thursday following the company's third quarter earnings report that missed analysts expectations for revenue and net income. Processing Content ...

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...